# EDGAR Filing Document

**Accession Number:** 0001813914
**File Stem:** 0000000000-23-002489
**Filing Date:** 2023-3
**Character Count:** 9706
**Document Hash:** d9583fc6ff73381cab5a030ee2d4710e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002489.hdr.sgml**: 20230919

**ACCESSION NUMBER**: 0000000000-23-002489

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230314

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CareMax, Inc.
- **CENTRAL INDEX KEY:** 0001813914
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-NURSING & PERSONAL CARE FACILITIES [8050]
- **IRS NUMBER:** 850992224
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 NW 57 COURT, SUITE 400
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126
- **BUSINESS PHONE:** 786-360-4768

**MAIL ADDRESS:**
- **STREET 1:** 1000 NW 57 COURT, SUITE 400
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Deerfield Healthcare Technology Acquisitions Corp.
- **DATE OF NAME CHANGE:** 20200602
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950170-22-003946

## Text-Extract

```

United States securities and exchange commission logo

                            March 14, 2023

       Kevin Wirges
       Chief Financial Officer and Treasurer
       CareMax, Inc.
       1000 NW 57th Court, Suite 400
       Miami, Florida 33126

                                                        Re: CareMax, Inc.
                                                            Form 10-K for the
Year Ended December 31, 2021
                                                            Form 10-Q for the
Period Ended September 30, 2022
                                                            Correspondence
Letter dated February 23, 2023
                                                            File No. 1-39391

       Dear Kevin Wirges:

               We have reviewed your February 23, 2023 response to our comment
letter and have the
       following comments. In some of our comments, we may ask you to provide
us with information
       so we may better understand your disclosure. Please respond to these
comments within ten
       business days by providing the requested information or advise us as
soon as possible when you
       will respond. If you do not believe our comments apply to your facts and
circumstances, please
       tell us why in your response. After reviewing your response to these
comments, we may have
       additional comments. Unless we note otherwise, our references to prior
comments are to
       comments in our January 25, 2023 letter.

       Form 8-K Filed March 9, 2023

       Exhibit 99.1, page 1

   1.                                                   We note your response
to comment 2. Given that you are continuing to present "de novo
                                                        pre-opening costs" and
"de novo post-opening costs" amounts, please disclose what each
                                                        of these amounts
represent and how they are calculated.
   2.                                                   We note your response
to prior comment 3. In regards to your presentation of Platform
                                                        Contribution, please
explain how you identified operating (loss) income as the
                                                        most directly
comparable financial measure calculated and presented in accordance with
                                                        Generally Accepted
Accounting Principles rather than gross profit. Please refer to Item
                                                        10(e)(i) of Regulation
S-K.
   3.                                                   Notwithstanding our
above comment on the most directly comparable GAAP measure to
                                                        Platform Contribution,
it is not clear why the cost of care amount presented in your
                                                        reconciliation does not
agree to the amount presented on your condensed consolidated
 Kevin Wirges
CareMax, Inc.
March 14, 2023
Page 2
         statements of operations. Please clarify. We also note you include a
line item called
         "other adjustments." As previously requested, please explain the
nature and
         corresponding amount of each material amount included in any "other
adjustments" line
         item.

4.       In your reconciliation of net income (loss) to Adjusted EBITDA, you
include an
         adjustment for "Transaction related restructuring costs." Please
disclose the nature of
         these costs. In your proposed disclosures provided in your letter
dated January 17, 2023,
         you included an adjustment specifically for DeSpac transaction and
related restructuring
         costs. If these costs are specific to the DeSpac transaction, please
specifically address in
         your disclosures why you are continuing to incur these costs in 2022.
5.       In your reconciliation to Adjusted EBITDA, the amounts presented for
acquisition related
         costs for the three months December 31, 2022 and December 31, 2021 as
well as the
         years ended December 31, 2022 and 2021 do not agree to the amount
reflected on your
         condensed consolidated statements of operations. Please advise.
Form 10-K for the Year Ended December 31, 2021

Platform Contribution and Adjusted EBITDA , page 44

6.       See our comments above regarding your Platform Contribution and
Adjusted EBITDA
         presentations.
       You may contact Nudrat Salik at (202) 551-3692 or Jeanne Baker at (202)
551-3691 if
you have any questions.

                                                                Sincerely,
FirstName LastNameKevin Wirges
                                                                Division of
Corporation Finance
Comapany NameCareMax, Inc.
                                                                Office of
Industrial Applications and
March 14, 2023 Page 2                                           Services
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 14, 2023

Kevin Wirges
Chief Financial Officer and Treasurer
CareMax, Inc.
1000 NW 57th Court, Suite 400
Miami, Florida 33126

Re: CareMax, Inc.

Form 10-K for the Year Ended December 31, 2021
Form 10-Q for the Period Ended September 30, 2022
Correspondence Letter dated February 23, 2023
File No. 1-39391

Dear Kevin Wirges:

We have reviewed your February 23, 2023 response to our comment letter and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our January 25, 2023 letter.

Form 8-K Filed March 9, 2023

Exhibit 99.1, page 1

1. We note your response to comment 2. Given that you are continuing to present "de novo pre-opening costs" and "de novo post-opening costs" amounts, please disclose what each of these amounts represent and how they are calculated.
2. We note your response to prior comment 3. In regards to your presentation of Platform Contribution, please explain how you identified operating (loss) income as the most directly comparable financial measure calculated and presented in accordance with Generally Accepted Accounting Principles rather than gross profit. Please refer to Item 10(e)(i) of Regulation S-K.
3. Notwithstanding our above comment on the most directly comparable GAAP measure to Platform Contribution, it is not clear why the cost of care amount presented in your reconciliation does not agree to the amount presented on your condensed consolidated

Kevin Wirges
CareMax, Inc.
March 14, 2023
Page 2

statements of operations. Please clarify. We also note you include a line item called "other adjustments." As previously requested, please explain the nature and corresponding amount of each material amount included in any "other adjustments" line item.

4. In your reconciliation of net income (loss) to Adjusted EBITDA, you include an adjustment for "Transaction related restructuring costs." Please disclose the nature of these costs. In your proposed disclosures provided in your letter dated January 17, 2023, you included an adjustment specifically for DeSpac transaction and related restructuring costs. If these costs are specific to the DeSpac transaction, please specifically address in your disclosures why you are continuing to incur these costs in 2022.

5. In your reconciliation to Adjusted EBITDA, the amounts presented for acquisition related costs for the three months December 31, 2022 and December 31, 2021 as well as the years ended December 31, 2022 and 2021 do not agree to the amount reflected on your condensed consolidated statements of operations. Please advise.

Form 10-K for the Year Ended December 31, 2021

Platform Contribution and Adjusted EBITDA, page 44

6. See our comments above regarding your Platform Contribution and Adjusted EBITDA presentations.

You may contact Nudrat Salik at (202) 551-3692 or Jeanne Baker at (202) 551-3691 if you have any questions.

Sincerely,

Division of Corporation Finance
Office of Industrial Applications and
Services